-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, February 8th.
Recently, the "2020 (Fifth) Sina Pharmaceutical Annual General Evaluation List" was officially announced, and Yiling Pharmaceutical won the "2020 Inheritance and Innovative Enterprise of Traditional Chinese Medicine"
.
Yiling Pharmaceutical inherits the essence of the traditional Chinese medicine culture, improves in inheritance, develops in inheritance, inherits and innovates and develops the theory of collateral disease in traditional Chinese medicine, and systematically constructs three theoretical frameworks for collateral disease research, which are major theoretical originals
.
Under the guidance of collateral disease theory, Yiling Pharmaceutical uses modern high-tech research and development and production of scientific and technological Chinese medicine to promote the industrialization of Chinese medicine.
Its products cover cardiovascular and cerebrovascular diseases, respiratory diseases, tumors, diabetes, nerves, urinary system diseases and other major diseases.
Disease field
.
At present, the company has more than ten patent medicine, of which 8 included in the national medical insurance catalog, five for the country-based pharmaceutical species
.
Among them, Lianhua Qingwen, Tongxinluo, and Shensongyangxin Capsules have annual sales of more than 1 billion yuan.
Lianhua Qingwen has played a major role in the fight against new coronary pneumonia and has become a viral respiratory public health event.
The representative Chinese patent medicine
.
Since its establishment in 1992, Yiling Pharmaceutical has always regarded "inheriting innovation and benefiting mankind" as its corporate purpose.
It has made great achievements in system innovation, theoretical innovation, technological innovation, product innovation, and technological innovation.
It has won six national science and technology awards
.
Among them, in January 2020, the project "Construction of Traditional Chinese Medicine Vein Theory and Its Guidance on Microvascular Disease Prevention and Treatment" completed by Hebei Yiling Medical Research Institute as the first principal research unit won the first prize of 2019 National Science and Technology Progress Award
.
According to reports, the national policy to vigorously promote the background, Yiling Pharmaceutical will further develop R & D and production advantages, heritage essence, honesty and innovation, promote Chinese medicine revitalization and development, accelerating the TCM medicine modernization, industrialization and internationalization, as in The development of medicine contributes to Ling's strength
.
Recently, the "2020 (Fifth) Sina Pharmaceutical Annual General Evaluation List" was officially announced, and Yiling Pharmaceutical won the "2020 Inheritance and Innovative Enterprise of Traditional Chinese Medicine"
.
Yiling Pharmaceutical inherits the essence of the traditional Chinese medicine culture, improves in inheritance, develops in inheritance, inherits and innovates and develops the theory of collateral disease in traditional Chinese medicine, and systematically constructs three theoretical frameworks for collateral disease research, which are major theoretical originals
.
Under the guidance of collateral disease theory, Yiling Pharmaceutical uses modern high-tech research and development and production of scientific and technological Chinese medicine to promote the industrialization of Chinese medicine.
Its products cover cardiovascular and cerebrovascular diseases, respiratory diseases, tumors, diabetes, nerves, urinary system diseases and other major diseases.
Disease field
.
At present, the company has more than ten patent medicine, of which 8 included in the national medical insurance catalog, five for the country-based pharmaceutical species
.
Among them, Lianhua Qingwen, Tongxinluo, and Shensongyangxin Capsules have annual sales of more than 1 billion yuan.
Lianhua Qingwen has played a major role in the fight against new coronary pneumonia and has become a viral respiratory public health event.
The representative Chinese patent medicine
.
Since its establishment in 1992, Yiling Pharmaceutical has always regarded "inheriting innovation and benefiting mankind" as its corporate purpose.
It has made great achievements in system innovation, theoretical innovation, technological innovation, product innovation, and technological innovation.
It has won six national science and technology awards
.
Among them, in January 2020, the project "Construction of Traditional Chinese Medicine Vein Theory and Its Guidance on Microvascular Disease Prevention and Treatment" completed by Hebei Yiling Medical Research Institute as the first principal research unit won the first prize of 2019 National Science and Technology Progress Award
.
According to reports, the national policy to vigorously promote the background, Yiling Pharmaceutical will further develop R & D and production advantages, heritage essence, honesty and innovation, promote Chinese medicine revitalization and development, accelerating the TCM medicine modernization, industrialization and internationalization, as in The development of medicine contributes to Ling's strength
.
